Between reference infliximab and biosimilar infliximab CT-P13 (Inflectra, Remsima), different recommendations exist for the clinical solutions. Recently, a research article, published in BioDrugs, assessed and compared the stability of the solutions prepared from the originator and the biosimilar using a set of characterization methods in line with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use recommendations.
Between reference infliximab and biosimilar infliximab CT-P13 (Inflectra, Remsima), different recommendations exist for the clinical solutions. Recently, a research article, published in BioDrugs, assessed and compared the stability of the solutions prepared from the originator and the biosimilar using a set of characterization methods in line with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use recommendations.
The investigators used reconstituted solutions of the reference and the biosimilar, and dilutions were stored in glass vials (10 mg and 2 mg per mL) or in polyolefin infusion bags (0.4 mg per mL), and were subsequently refrigerated between 2°C and 8°C for 2 weeks.
The distribution of particulates was studied over a range of 0.001—1.0 µm by dynamic light scattering (DLS). Oligomers were analyzed by native size-exclusion ultra-high–performance liquid chromatography with ultraviolet (UV) visible detection coupled to native mass spectrometry (MS); MS was also used to evaluate natural aggregates and the isoform profile, and DLS was also used to detect gross conformational changes by tracking the hydrodynamic radius.
The secondary structure of the proteins was studied by far UV circular dichroism, while the tertiary structure was assessed by intrinsic tryptophan fluorescence. Reverse-phase ultra-high-performance liquid chromatography with UV detection was used to analyze intact reference and biosimilar infliximab for quantification.
Functionality was evaluated through biological activity as measured by the extension of the immunological reaction of the infliximab agents with tumor necrosis factor by enzyme-linked immunosorbent assay.
The authors write that the stress applied to both the reference and biosimilar solutions showed similar levels of aggregate formation, structural variation, and chemical modification. Only 1 notable difference emerged: in freeze-thaw cycles, CT-P13 was slightly more robust.
CT-P13 and the reference showed identical far UV circular dichroism spectra, which did not change over time. No significant changes were found in tertiary structure, and no aggregate process was noted during the period of the study. No meaningful differences emerged in the hydrodynamic radius of the solutions over time, and the concentration of infliximab in both products remained constant.
The 2 products have different glycosylation patterns, so differences in the native MS profile were found, which was expected. No important modifications developed over time.
The product’s function was maintained over the 60-day test period, and it was similar in all solutions tested.
The authors concluded that there were high levels of similarity between the reference and the biosimilar, and that when prepared and stored as normally used in the hospital pharmacy, all solutions showed physiochemical and functional stability.
Reference
Hermosilla J, Sánchez-Martín R, Pérez-Robles R, et al. Comparative stability studies of different infliximab and biosimilar CT-P13 clinical solutions by combined use of physiochemical analytical techniques and enzyme-linked immunosorbent assay (ELISA). BioDrugs. 2019;33(2):193-205. doi: 10.1007/s40259-019-00342-9.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.